Clinical Trials Logo

T-cell Prolymphocytic Leukemia clinical trials

View clinical trials related to T-cell Prolymphocytic Leukemia.

Filter by:

NCT ID: NCT05978141 Recruiting - Clinical trials for Angioimmunoblastic T-cell Lymphoma

A Registry for People With T-cell Lymphoma

Start date: July 27, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

NCT ID: NCT05823571 Recruiting - Multiple Myeloma Clinical Trials

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Start date: July 6, 2023
Phase: Phase 1
Study type: Interventional

This research is being done to learn whether drug called itacitinib, which is a novel inflammation- and immune-lowering drug (immunosuppressant), can be given before and after non-myeloablative peripheral blood stem cell transplantation (PBSCT; also known as a 'mini' transplant) to help prevent certain complications such as cytokine release syndrome (CRS) for patients with blood cancers, using peripheral blood from a relative. The investigators will also examine if by using itacitinib the investigators can reduce the duration of MMF (other immune suppressive drug administration posttransplant).

NCT ID: NCT05010005 Active, not recruiting - Clinical trials for T-cell Large Granular Lymphocyte Leukemia

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Start date: August 12, 2021
Phase: Phase 1
Study type: Interventional

This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma.

NCT ID: NCT04771572 Recruiting - Multiple Myeloma Clinical Trials

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Start date: August 23, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

NCT ID: NCT04312841 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Start date: September 15, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well letermovir works for the prevention of cytomegalovirus reactivation in patients with hematological malignancies treated with alemtuzumab. Patients receiving treatment with alemtuzumab may experience cytomegalovirus reactivation. Letermovir may block cytomegalovirus replication and prevent infection.

NCT ID: NCT03989466 Active, not recruiting - Clinical trials for T-Cell Prolymphocytic Leukemia

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

Start date: January 15, 2020
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the side effects and best dose of alemtuzumab when given together with itacitinib in treating patients with T-cell prolymphocytic leukemia. Itacitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with alemtuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving itacitinib and alemtuzumab may work better in treating patients with T-cell prolymphocytic leukemia compared to standard of care treatment.

NCT ID: NCT02742727 Recruiting - Clinical trials for Acute Myeloid Leukemia

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

Start date: March 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with CD7 positive relapsed or refractory Leukemia and Lymphoma.

NCT ID: NCT02689453 Completed - Clinical trials for T-Cell Prolymphocytic Leukemia

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Start date: January 19, 2017
Phase: Phase 1
Study type: Interventional

Background: Adult T-cell leukemia (ATL) is a rare blood cancer. Researchers want to see if a combination of two drugs - recombinant human interleukin 15 (rhIL-15) and alemtuzumab - is a better treatment for ATL. Objectives: To test if giving rhIL-15 combined with alemtuzumab improves the outcome of therapy for ATL. Also, to determine the safe dose of this combination and identify side effects and effects on the immune system. Eligibility: Adults 18 years and older with chronic or acute ATL who have not been helped by other treatments. Design: Participants will be screened with tests that are mostly part of their usual cancer care. They will sign a separate consent form for this. Weeks 1 and 2: Participants will have a total of 10 visits. They will: - Get rhIL-15 under the skin by needle. - Have a physical exam and vital signs measured. - Give blood samples. - Answer questions about their health and their medicines. Week 3: Participants will stay in the clinic. They will: - Get alemtuzumab infusions in a vein through a small catheter on days 1, 2, 3, and 5. - Take medicines to decrease side effects. - Have a computed tomography (CT) scan to evaluate the treatment. - Have a physical exam and vital signs measured. - Give blood samples. Answer questions about their health and medicines. Weeks 4, 5, and 6 will repeat week 3, without the CT scan. Some patients will just have outpatient visits these weeks. After treatment, participants will have follow-up visits every few months for up to 2 years. At these visits, participants will give blood samples and have CT scans.

NCT ID: NCT01251575 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Start date: December 1, 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well sirolimus, cyclosporine and mycophenolate mofetil works in preventing graft-vs-host disease (GVHD) in patients with blood cancer undergoing donor peripheral blood stem cell (PBSC) transplant. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving total-body irradiation together with sirolimus, cyclosporine, and mycophenolate mofetil before and after transplant may stop this from happening.

NCT ID: NCT01186640 Completed - Clinical trials for T-cell-prolymphocytic Leukemia

Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)

Start date: June 2010
Phase: Phase 2
Study type: Interventional

Study hypothesis: Simultaneous FMC-Alemtuzumab administration followed by Alemtuzumab maintenance therapy in patients with T-PLL is feasible, safe and efficient.